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Abstract
Background: Chemokines and chemokine receptors are major actors of leukocytes trafficking and some have been
shown to play an important role in cancer metastasis. Chemokines CCL19, CCL20 and CCL21 and their receptors
CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer.
Methods: Biomarker expression levels were evaluated using immunohistochemistry on paraffin-embedded tissue
sections of breast cancer (n = 207).
Results: CCR6 was expressed by tumor cells in 35% of cases. CCR7 was expressed by spindle shaped stromal cells
in 43% of cases but not by tumor cells in this series. CCL19 was the only chemokine found expressed in a
significant number of breast cancers and was expressed by both tumor cells and dendritic cells (DC). CCR6, CCL19
and CCR7 expression correlated with histologic features of aggressive disease. CCR6 expression was associated with
shorter relapse-free survival (RFS) in univariate and but not in multivariate analysis (p = 0.0316 and 0.055
respectively), and was not associated with shorter overall survival (OS). Expression of CCR7 was not significantly
associated with shorter RFS or OS. The presence of CCL19-expressing DC was associated with shorter RFS in
univariate and multivariate analysis (p = 0.042 and 0.020 respectively) but not with shorter OS.
Conclusion: These results suggest a contribution of CCR6 expression on tumor cells and CCL19-expressing DC in
breast cancer dissemination. In our series, unlike what was previously published, CCR7 was exclusively expressed on
stromal cells and was not associated with survival.
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Background
Most breast cancer deaths are due to metastatic relapse
after treatment of apparently localized disease, and occult
dissemination of tumour cells occurs at this early phase
[1,2]. Post-operative systemic therapies (chemotherapy,
endocrine therapy and more recently passive immunother-
apy/targeted therapy with anti-HER2 monoclonal anti-
body) have been shown to improve recurrence-free and
overall survival in patients with early breast cancer [3,4].
Molecular mechanisms of metastastic dissemination and
most notably the biological mechanisms underlying organ
specificities of metastatic dissemination are only partially
understood [5,6]. The dissemination of breast carcinoma
cell outside the organ of origin involves multiple steps, e.g.
loss or deregulation of normal cell-cell contacts, produc-
tion of enzymes remodelling the extracellular matrix, pro-
duction of motility factors and acquisition of migratory
capabilities. Several studies have reported that the chemo-
kines/chemokine receptors system can be high jacked by
epithelial tumor cells and may contribute to tumor cell
dissemination [5,7-11].
Chemokine are low molecular weight proteins signal-
ling through G-protein linked 7-transmembrane recep-
tors and regulating the trafficking of leukocytes to
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migration towards the chemokine source [12]. Chemo-
kines can be divided into inflammatory chemokines and
homeostatic chemokines [13]. Chemokine and chemo-
kine receptors have been recently identified as potential
actors of the metastatic process [5,10]. Several chemo-
kine receptors have been associated with cancer
dissemination.
In the present study we sought to assess the presence
of CCR6 and CCR7 receptors and their ligands in non-
metastatic primary breast carcinomas. CCR6 and CCR7
were chosen because they are physiologically involved in
the migration of immune cells to peripheral tissues and
lymph nodes respectively. CCR6 is a chemokine receptor
expressed on immature DC that binds CCL20 (also
called Macrophage Inflammatory Protein (MIP) - 3a)a t
inflamed sites and promotes cell migration to peripheral
tissues. Conversely, CCR7 is expressed on both mature
DC and T lymphocytes [14,15] and binds CCL19 (also
called MIP3b) and CCL21 (also called 6Ckine) chemo-
kines which are expressed by efferent lymphatic vessels
and secondary lymphoid organs, in particular lymph
nodes[16]. Binding of CCR7 by its ligands promotes cell
migration to secondary lymphoid organs [16].
C C R 7h a sb e e nr e p o r t e dt ob ee x p r e s s e do nc a n c e r
cells from various origins [11,17-19], including breast
cancer cells, and its expression correlates with lymph
node involvement and to some extent with prognosis
[7,8]. CCL20 is the sole known ligand for CCR6. CCL20
and/or CCR6 expression have been reported in pancrea-
tic and colorectal cancer and correlates with invasion
and liver metastasis [20-22]. In breast cancer, CCL20
was found to be expressed by cancer cells and correlate
with infiltration by immature DC [23,24].
In the present study, we assessed the expression of
CCR6, CCR7 and their ligands CCL19, CCL20 and
CCL21 using immunohistochemistry in a series of
tumors prospectively collected from patients with loco-
regional breast cancer treated at the Centre Léon Bérard
in 1996 and 1997. Results were reported in accordance
with the “Reporting recommendations for tumor marker
prognostic studies (REMARK)” [25]
Methods
Patients’ selection
Clinical data from patients with early breast cancer
operated at the Centre Léon Bérard were prospectively
entered in a regularly updated institutional database
since 1996 and paraffin embedded tumor specimen
from these patients were stored. All patients with non-
metastatic invasive primary breast carcinomas were eli-
gible for this study, provided that sufficient tumor mate-
rial was available for immunohistochemical analysis.
One hundred and fifty six of 217 tumors met the
eligibility criteria for the year 1996 and the first 100
eligible tumors (among 249 breast tumor samples)
from the year 1997 were selected. Of these 256 tumor
samples, those of 46 patients were excluded: 2 patients
were men, 8 patients were recognized to have metastatic
disease at the time of surgery, 17 patients received
neoadjuvant chemotherapy (therefore the tumor sample
could only be analyzed after exposure to cytotoxic che-
motherapy), 16 had a previous history of invasive breast
cancer (in most cases contralateral) and 3 patients had
synchronous bilateral tumors. Three further tumor sam-
ples were found to be duplicates. Although 256 tumor
specimens were analysed for CCR6, CCR7, CCL19,
CCL20, CCL21, outcome analysis and correlation with
histological and clinical parameters was therefore per-
formed on 207 patients. Median follow up in the series
for surviving patients was estimated to be 10 (range
9.8-10.1) years.
Treatment
The following standard therapeutic procedures in the
center were applied to these patients: patients with cen-
tral, multiple tumors or tumors larger than 3 cm, were
treated with radical mastectomy, while conservative sur-
gery followed by radiotherapy was the standard treat-
ment for the remaining patients; patients with nodal
involvement and patients with node negative tumors
and two or more adverse prognostic factors (tumor lar-
ger than 3 cm, Scarff-Bloom-Richardson (SBR) grade 3
tumors, lack of estrogen (ER) and progesterone receptor
(PgR) expression, or age under 35 years) received 6
cycles of anthracyclin-containing adjuvant chemother-
apy. Anthracyclin-containing adjuvant chemotherapy
was also given to all patients with T4d tumors (inflam-
matory breast cancer); adjuvant therapy with tamoxifen
20 mg/day was given for 5 years to patients with ER
and/or PgR expressing tumors. Given the timeframe of
our study none of the patients received adjuvant
trastuzumab.
Immunohistochemistry
Paraffin-embedded breast tumors were serially sectioned
at a thickness of 4 μm. After deparaffinization and rehy-
dration, endogenous peroxidases were blocked by incu-
b a t i n gt h es l i d e si n5 %h y d r o g e np e r o x i d ei ns t e r i l e
water. For heat induced antigen retrieval, tissue sections
were boiled in 10 mM citrate buffer pH6 using a micro-
wave for 15 minutes [mouse anti-CCR6 clone 53103-
111 (R&D Systems, Minneapolis, USA), goat polyclonal
anti-CCL19/MIP3b (R&D Systems, Minneapolis, USA)
antibodies], or a water bath for 40 minutes [goat poly-
clonal anti-CCL21-6Ckine (R&D Systems, Mineapolis,
USA), and mouse anti-CCL20/MIP3a clone 308B7
(Schering-Plough, Dardilly, France) antibodies]. No
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clone 2H4 (Pharmingen, San Diego, USA) antibody.
Non-specific binding was blocked with a protein
blocking reagent (Immunotech, Marseille, France) for 5
minutes except for anti-CCL19 (15 minutes). Slides
were then incubated at room temperature for one hour
with the primary specific antibody that was diluted
using an antibody diluent solution (Chem Mate, Dako,
Trappes, France) at 1/1500 for anti-CCR6, 1/25 for anti-
CCL19, 1/50 for anti-CCL21, 1/200 for anti-CCL20 and
1/500 for anti-CCR7 antibodies. The primary antibody
was replaced by a non immune serum for negative con-
trol slides. Slides were rinsed in phosphate buffered sal-
ine (PBS), and then incubated with a biotinylated
secondary antibody bound to a streptavidin peroxidase
conjugate (Ultratech HRP DAB kit, Immunotech, Mar-
seille, France). The bound antibody was revealed by add-
ing the substrate: 3,3’-diamino benzidine. Sections were
counterstained with hematoxylin. All slides were read by
a single senior pathologist (I.T.) who was blinded to the
clinical data. Upon the observation of the first 30 breast
cancer cases, a grading system was defined for CCR7 in
which the density of positive stromal cells within the
tumor was assessed semi quantitatively (4 digit system).
This classification defined four groups as follows:
tumors were classified as negative, or with low, inter-
mediate or high density of positive cells as determined
by the number of positive cells in at least 5 low power
fields (x10) within the high staining spots. A slide which
was representative for each group was then used as con-
trol for the analysis of the subsequent cases. For antibo-
dies against CCR6 and CCL20, both the intensity of
cytoplasmic staining (3 grades) and the percentage of
positive tumor cells were assessed. For CCL19, both the
percentage and intensity of positive tumor cells and the
presence or absence of CCL19 positive DC were noted.
Tumors were classified as negative, or with low, mid
and high density of positive tumor cells. The few cases
o fd i s c o r d a n c ew e r er e v i e w e db yo t h e ri n v e s t i g a t o r s( S .
G., P.A.C. or J-Y.B.) to reach a consensus.
Statistical analysis
The correlation between the clinical and biological data
and the phenotype of both tumor and stromal cells
within the tumor was performed using the c
2 test,
Fisher exact test or non parametric tests where appro-
priate. For statistical analysis the semi-quantitative grad-
ing used for description of tumor samples was
simplified to a 2 class system. For CCR7, tumors with
low or no staining were considered negative. For CCR6
and CCL19, tumors with staining on less than 10% of
tumor cells were considered negative while tumors with
more than 10% of tumor cells stained were considered
positive. Survival curves were plotted using the Kaplan
Meier method, and were compared using the Log Rank
test [26]. Multivariate analysis of prognostic factors for
overall and relapse free survival were performed using a
Cox model regression. No attempt was made to adjust
for multiples tests. Data extraction and all statistical
analysis were done using the procedures of the SPSS
12.0.1 package. This study was approved by the Comité
de Protection des Personnes SUD-EST-IV ethics commit-
tee in Lyon
Results
Patients characteristics
The main characteristics of the patients are summarized
in table 1. Median age was 56 (30-88) years, most
tumors were 20 mm or smaller, 101 of 207 (48%)
patients had node-positive tumors. Among patients with
node-positive tumors, most (65 of 101, 64%) had 1 to 3
positive lymph nodes. The main histology was ductal
carcinoma (83%), followed by lobular histology (11%)
and approximately 5% of patients had non-ductal, non-
lobular histology. One hundred and seventy four
patients (84%) had hormone receptor-positive tumors
(estrogen and/or progesterone receptor), 124 tumors
expressed both estrogen and progesterone receptor by
immunohistochemistry (IHC). HER2 was overexpressed
(i.e. HER2 3+ on IHC and/or HER2 amplification on
FISH) in 22 tumors (10.6%). Twenty five patients
(12.1%) had triple negative breast cancer.
Chemokines and chemokine receptors expression on
tumor samples
CCR6 expression was not detectable on normal breast
tissue (not shown). In contrast, tumor cells expressed
CCR6 in 72 samples (35%) (Figure 1A &1B and Table
1). Within the same tumor, staining was not uniform,
the proportion of positive tumor cells varied from 10%
to 100%. CCR6+ stromal cell were rarely detected.
CCR6+, CD1a+ and Langerin+ tumor-infiltrating DC
were occasionally identified in serial tissue sections from
the same tumor (not shown). Although CCL20, a ligand
of CCR6, was detectable in breast cell culture and fro-
zen breast cancer tissue [24], it was not detectable in
any paraffin embedded tumor samples in this series.
Therefore only CCR6+ tumors cells were considered for
analysis.
No CCR7+ stromal cells were detected in normal
breast tissues (not shown). In contrast, 89 tumors (43%)
in this series contained CCR7+ cells (Figure 1C, D, E
&1F and table 1). In contrast to what was previously
reported CCR7 [7,8] was not found to be expressed by
tumor cells, but mostly by cells with myofibroblastic
morphology within the stroma (Figure 1D). Those cells
were either spread or assembled in bundles within the
tumor stroma. The fibroblast-like morphology of these
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smooth muscle actin (a-SMA) suggests that these cells
might be myofibroblasts (Figure 1I &1J). Indeed these
cells did not express caldesmone (Figure 1K: SMA,
Figure 1L: caldesmone). In a minority of samples, a few
CCR7+ cells with a dendritic morphology were observed
(Figure 1F) but not retained for analysis.
CCL19, a ligand of CCR7, was expressed on tumor
cells in 109 tumor samples (53%) (Figure 1M, Figure 1N
and Table 1). Furthermore, CCL19-expressing with
interdigited shape were found scattered in the inflam-
matory infiltrate in 101 tumor samples (49%)(Figure 1O
&1P and Table 1). These cells also express CD1a
(Figure 1P) and Langherin (additional file 1), which lead
us to identify those cells as dendritic cells. CCL21 was
expressed at low levels in only 9 of the first 156 patients
(6%) (not shown) and for this reason its expression was
not further investigated in the rest of the series.
Association of chemokines and chemokine receptors
expression with clinicopathological variables
Scarff Bloom Richardson tumor (SBR) grade was the
only clinico-pathological variable associated with CCR6
expression on tumor cells (expression was associated
with higher grade, p = 0.002). CCR7 expression on stro-
mal cells was associated with lymph node involvement
(but not with the number of lymph node involved),
ductal histology, higher SBR grade and HER2 overex-
pression (p values 0.033, 0.006, 0.001 and 0.042 respec-
tively). CCL19/MIP3b expression on tumor cells and
DC had a different distribution among tumor samples
were therefore analysed as two distinct biomarkers.
CCL19/MIP3b expression on tumor cells was associated
with higher tumor grade (p = 0.025). Tumor infiltration
by CCL19/MIP3b-expressing DC was associated with
both higher tumor grade (p = 0.040) and HER2 overex-
pression (p = 0.015). There was no significant difference
in the proportions of cases with CCR6 positive tumor
cells, CCR7 positive stromal cells, CCL19 positive den-
dritic cells, CCL19 positive tumor cells between cases
classified as triple negative and cases that were not clas-
sified as such (p = 1.000; 0.392; 0.828 and 0.276
respectively).
Association of chemokines and chemokine receptors
expression with relapse-free and overall survival
In univariate analysis, using the log rank test, larger
tumor size (p = 0.0004), nodal involvement (p = 0.0036),
SBR grade (p = 0.0028), lack of estrogen and progester-
one receptor expression (p = 0.0123 and 0.0132 respec-
tively), CCR6 expression (p = 0.0316)(Figure 2A) and
infiltration by CCL19/MIP3b-expressing DC (p =
0.0417)(Figure 2B) were associated with shorter relapse-
free survival (RFS). Interestingly, HER2 was not signifi-
cantly associated with prognostic in our series, likely
due to the small number of cases with HER2 overex-
pression (Table 2). Results of univariate analysis are
summarised in Table 2. Multivariate analysis was con-
ducted using a Cox proportional hazard model. In mul-
tivariate analysis only tumor size, node involvement and
infiltration by CCL19-expressing DC were significantly
Table 1 Main characteristics of 207 patients with
locoregional breast cancer
Characteristics N %
Total 207 100
Age (range) 56 (30-88)
Tumor size
T1 121 58,50%
T2 76 36,70%
T3-T4 10 4,80%
Lymph node
Negative 106 51,20%
Positive 101 48,80%
Histology
Ductal 173 83,60%
Lobular 24 11,60%
Other 10 4,80%
Tumor grade (Scarff-Bloom-Richardson)
1 52 25,10%
2 96 46,40%
3 59 28,50%
Estrogen receptor
Negative 53 25,60%
Positive 153 73,90%
Progesterone receptor
Negative 61 29,50%
Positive 145 70,00%
Her2-neu expression (IHC)
0, 1+ or 2+ 182 87,90%
3+ 22 10,60%
Unknown 3 1,40%
CCR6 expression on Tumor cells
Negative 130 64,4%
Positive 72 35,6%
CCR7 expression on Stromal cells
Negative 118 57,0%
Positive 89 43,0%
CCL19 expression on Tumor cells
Negative 95 46,6%
Positive 109 53,4%
CCL19 expression on Dendritic cells
Negative 103 50,5%
Positive 101 49,5%
IHC: assessed by immunohistochemistry.
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Figure 1 Chemokine and chemokine receptor expression on breast tumor samples. P a n e l sA&B :CCR6 expression in breast tumors.
Panel A: CCR6 negative tumor cells (× 40), and panel B: CCR6 positive tumor cells (× 40,). Panels C, D, E & F: CCR7 expression on tumor-
infiltrating cells (× 20, panel C, × 20 panel D and × 40, panel E), panel F, CCR7+ infiltrating cells with dendritic cell morphology (× 20). Panels G,
H, I & J: Adjacent sections (× 20 and × 40) showing elongated “fibroblastic cells” within the tumor stroma, positive for both CCR7 (panel G &H)
and smooth muscle actin (SMA) (panel I & J). Panels K & L: staining of SMA (panel K) and caldesmone (panel L) showing lack of caldesmone
staining of the SMA positive myofibroblastic cells. Panels M & N: CCL19/MIP3 b expression on tumor cells: panel M: negative tumor cells (× 40);
panel N: positive tumor cells (× 40); Panel O & P: CCL19 (panel O, × 20) and CD1a (panel P, × 40) expression on cells with dendritic cell
morphology in the tumor stroma. Bars are all 50 microns.
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0.047 respectively)(Table 3). The association of CCR6
expression in tumor cells with shorter RFS in univariate
analysis did not remain statistically significant in the
multivariate analysis. None of the biomarker analysed in
our study showed a significant association with overall
survival (OS) neither in univariate analysis (Table 2) nor
in multivariate analysis (Table 3).
CCR7-stromal cells are found in metastatic axillary lymph
nodes
Since CCR7 is involved in the migration of DC and T
cells from peripheral tissues to the draining axillary
lymph nodes, the presence of CCR7-expressing stromal
cells was investigated in axillary lymph nodes (LN)
(Figure 3A &3B). The lymph nodes and primary tumor
of 49 randomly selected patients were examined, 34
patients had lymph node invasion and 15 had no lymph
node invasion. A total of 184 lymph nodes were analysed,
85 of them were invaded by tumor cells (18 micro-metas-
tases and 67 macro-metastases). Among the patients with
lymph node positive tumors, 3 LN from 2 patients with
micro-metastases could not be analysed because of insuf-
ficient material left, while for 3 other patients, CCR7
expression could not be assessed in the primary tumor.
No CCR7+/a-SMA+cells could be observed in normal
LN (i.e. without tumor cells) whether from node-negative
or node positive axillary LN dissection (not shown).
However, a few CCR7+/a-SMA- cells with dendritic
morphology were scattered among T cells and were iden-
tified as mature interdigitating DC. In contrast, CCR7
+/a-SMA+ stromal cells were observed in 34 of 85
tumor-invaded LN, most often in the “histiocytic” areas
of the lymph node, in or beneath the sub-capsular sinus
(Figure 3A). All CCR7-expressing stromal cells were
observed in the invaded axillary lymph nodes of 15 of the
21 patients whose primary tumors contained CCR7-
expressing stromal cells versus 0 of the 8 patients with
CCR7-negative tumors (p = 0.001)(Figure 3C). CCR7-
expressing stromal cells had the same morphology and
distribution in the primary tumor and in the invaded
lymph nodes (Additional file 2). Of note, in 3 of 3 lymph
nodes where metastatic cells had eroded the LN capsule,
CCR7+/a-SMA+ stromal cells were observed at the front
line of capsular invasion (Figure 3B). In the regional axil-
lary lymph nodes, CCR7+ myofibroblasts are therefore
observed only in case of nodal involvement by tumor
cells and only from primary tumors containing CCR7-
expressing stromal cells.
Discussion
The dissemination of breast carcinoma cell outside the
organ of origin involves multiple steps, e.g. loss or
deregulation of normal cell-cell contacts, production of
enzyme remodelling the extracellular matrix, production
of motility factors and acquisition of migration capaci-
ties. Several studies have reported that chemokines and
their receptors can be expressed by epithelial tumor
cells and may contribute to cell migration [5,7-11].
The objective of the present study was to investigate
the presence of CCR6 and CCR7 chemokine receptors
and their ligands in non-metastatic primary breast
Figure 2 Relapse-free survival (RFS) according to CCR6 and CCL19 expression. Panel A: relapse-free survival according to CCR6 expression
in tumor cells. Panel B: relapse-free survival according to the presence of CCL19-expressing dendritic cells (DC).
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Page 6 of 10carcinomas. CCR6 and CCR7 were chosen because they
are physiologically involved in the migration of immune
cells to peripheral tissues and lymph nodes respectively.
Expression of these chemokine and chemokine receptors
was assessed using IHC. CCR6, CCR7 and CCL19 were
found to be expressed in a large proportion of tumors
and were, in most cases, associated with features of
more aggressive disease, such as higher histological
grade and HER2 overexpression. We could not detect
any CCL20 expression in our series using IHC on paraf-
fin embedded tissue sample while we were previously
able to show CCL20 expression on frozen tissue section
[24], using a different antibody. Lack of CCL20 detec-
tion in our series may therefore be regarded as a techni-
cal limitation. CCL21 was expressed at low levels in
very few tumors in this series. Further studies, using dif-
ferent techniques such as quantitative RT-PCR or pro-
tein extraction on frozen samples, will be needed to
Table 2 Summary of univariate analysis
Characteristics N Mean RFS (years) 95% CI p value for LR Mean OS (years) 95% CI p value for LR
Age (range)
< 40 years 15 8.1 6.3-10.0 10.6 10.1-11.1
40-55 years 82 11.1 10.5-11.7 11.2 10.7-11.8
> 55 years 110 10.3 9.6-11.1 0.084 10.2 9.5-10.9 0.051
Tumor size
T1 121 11.1 10.6-11.7 11.1 10.6-11.7
T2 76 10.0 9.1-10.8 10.5 9.9-11.2
T3-T4 10 6.1 2.9-9.4 < 0.001 6.6 3.6-9.6 < 0.001
Lymph node
Negative 106 11.0 10.5-11.7 11.2 10.7-11.7
Positive 101 10.0 9.2-10.7 0.031 10.1 9.4-10.8 0.030
Histology
Ductal 173 10.6 10.0-11.1 10.6 10.1-11.1
Lobular 24 10.5 9.1-11.9 11.5 10.8-12.3
Other 10 9.8 7.4-12.3 0.722 10.4 7.8-12.9 0.410
Tumor grade (Scarff-Bloom-Richardson)
I 52 11.9 11.4-14.4 11.7 11.1-12.3
II 96 10.4 9.6-11.1 10.6 10.0-11.2
III 59 9.4 8.2-11.1 0.003 9.9 8.9-10.9 0.024
Estrogen receptor
Negative 53 9.6 8.4-10.7 10.2 9.2-11.2
Positive 153 11.0 10.5-11.5 0.012 11.0 10.5-11.5 0.354
Progesterone receptor
Negative 61 9.5 8.4-10.6 9.9 9.0-10.9
Positive 145 11.1 10.6-11.6 0.013 11.2 10.7-11.6 0.035
Her2-neu expression (IHC)
0, 1+ or 2+ 182 10.6 10.1-11.1 10.7 10.3-11.2
3+ 22 9.7 8.4-10.9 0.819 10.1 9.2-11.0 0.886
CCR6 on tumor cells
Negative 130 11.0 10.4-11.6 10.9 10.3-11.4
Positive 72 9.9 9.0-10.8 0.032 10.5 9.8-11.2 0.400
CCR7 on stromal cells
Negative 118 10.8 10.2-11.5 11.0 10.5-11.6
Positive 89 10.3 9.4-11.1 0.344 10.4 9.6-11.1 0.153
CCL19 on tumor cells
Negative 95 10.4 9.6-11.2 10.7 10.0-11.3
Positive 109 10.7 10.0-11.4 0.730 10.8 10.2-11.4 0.962
CCL19 on dendritic cells
Negative 103 11.0 10.4-11.7 11.0 10.3-11.5
Positive 101 9.8 9.1-10.6 0.042 10.2 9.6-10.9 0.271
IHC: assessed by immunohistochemistry.
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primary breast cancer. CCR6 was detectable in tumor
cells, while CCL19 was expressed by both tumor cells
and stroma-infiltrating cells exhibiting a dendritic mor-
phology. In this series CCR7 was found to be expressed
only on stromal cells either with myofibroblastic
morphology and a-SMA expression or with dendritic
morphology, but not on tumor cells. In previously
reported series, CCR7 expression had been described on
tumor cells from breast cancer [7,8] as well as from other
tumors such as gastric and lung cancer [11,19] but not
on cells in the tumor stroma. The reasons for this discre-
pancy are not clear, and may possibly reflect different
methods used for IHC staining. Indeed, André et al [7]
and Cabioglu et al [8] both used the same anti-CCR7
antibody, but with different peroxydase bloking agents
and different antibody incubation time. (Cabioglu et al
2005 [8] and F. André, personal communication). The
precise nature of these CCR7-expressing cells remains
unclear. Despite the fact that CCR7 was found on stro-
mal cells in the present study this feature was still signifi-
cantly associated with node involvement. However,
unlike what was previously reported and despite the fact
the CCR7-expression on stromal cells was associated
with several features of aggressive disease, we were
unable to show any correlation between CCR7 expression
and poorer outcome whether in univariate or multivari-
ate analysis. This finding also raises concerns on the con-
sistency and interpretation of IHC studies and therefore
on the role of IHC in the identification of biomarkers.
CCR6 was expressed on tumor cells and its expression
was associated with shorter relapse-free survival in uni-
variate but not in multivariate analysis, and its impact
on overall survival was not statistically significant.
Although CCR6 expression has been reported in several
cancers and usually correlates with more aggressive dis-
ease [20,21,27], it’s association with shorter RFS has
never been demonstrated before. CCR6 may increase
tumor cells’ motility and therefore their metastatic
potential by acting on the cytoskeleton, as has been
described in a model of colonic epithelium [28].
We also found that tumor infiltration by CCL19-
expressing DC was associated with shorter relapse-free
survival in both univariate and multivariate analysis.
However since mature DCs are known to express both
CCR7 and CCL19 [29] the patho-physiological meaning
of this finding is unclear. Indeed since we did not use
other markers of DC, this finding may reflect the fact
that tumor infiltration by DC is of poor prognosis as
suggested in a previous report[30].
Finally, we found that CCR7-expressing stromal cells
were also present in lymph nodes invaded by tumor
cells but this finding was restricted to the patients who
had CCR7-expressing stromal cells in their primary
tumor. This finding suggests that tumor cells may be
able to recruit CCR7-expressing stromal cells.
Conclusion
Our results suggest that CC R 6e x p r e s s i o no nt u m o r
cells and that infiltration by CCL19-expressing DC
Table 3 Summary of multivariate analysis
Relapse-free survival
Variable Hazard
Ratio
95% CI p value
Tumor size (mm) 1.031 [1.005-1.056] 0.018
Number of positive node 1.086 [1.030-1.155] 0.002
SBR grade 2 (ref. SBR1) 1.945 [0.551-6.871] 0.302
SBR grade 3 (ref. SBR1) 2.349 [0.628-8.794] 0.205
Estrogen receptor (negative) 1.527 [0.658-3.543] 0.325
Progesterone receptor
(negative)
1.424 [0.6593-
3.102]
0.374
CCR6+ tumor cells 1.929 [0.986-3.772] 0.055
CCL19+ DC 2.277 [1.141-3.772] 0.020
Overall Survival
Variable Hazard
Ratio
95% CI p value
Tumor size (mm) 1.027 [1.006-1.049] 0.012
Number of positive node 1.118 [1.066-1.173] < 0.001
SBR grade 2 (ref. SBR1) 1.534 [0.549-4.287] 0.415
SBR grade 3 (ref. SBR1) 1.931 [0.666-5.605] 0.226
Progesterone receptor
(negative)
1.419 [0.751-2.678] 0.281
CCR6+ tumor cells 1.205 [0.638-2.277] 0.565
CCL19+ DC 1.717 [0.916-3.219] 0.092
SBR: Scarff-Bloom-Richardson grade; ref.: reference for analysis; CCR6+: CCR6-
positive; CCR19+ DC: CCR19-positive dendritic cells.
AB
C
CCR7+ SMA+ stromal cells in the 
primary tumor
Yes No
CCR7+ SMA+ 
stromal cells in 
the lymph nodes
Yes 15 0
No 6 8
Figure 3 CCR7-expressing stromal cells infiltrate metastatic
lymph nodes. Panels A & B: CCR7+ myofibroblasts in axillary
lymph nodes (LN) of node positive tumors (panel A) and CCR7+
myofibroblasts in an invaded lymph node with capsular invasion
(panel B). Panel C: Number of patients with CCR7+stromal cells
among patients with positive lymph nodes (for tumor invasion)
according to the presence of CCR7+ stromal cells in the primary
tumor, p = 0.001 (Fisher’ test).
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Page 8 of 10contributes to breast cancer dissemination. In our series,
unlike what was previously published, CCR7 was exclu-
sively expressed on stromal cells and was not associated
with survival.
Additional material
Additional file 1: Langherin expression on dendritic cells in the
stroma of breast cancer. Panel A ×20 and Panel B ×40.
Additional file 2: CCR7-expressing stromal cells display the same
morphology and distribution pattern in primary tumor and
matching invaded lymph nodes. Panels A-D, Case 1: lymph node × 20
(panel A), lymph node × 40 (panel B), primary tumor × 20 (panel C),
primary tumor × 40 (panel D). Panels E-H, case 2: lymph node × 20
(panel E), lymph node × 40 (panel F), primary tumor × 20 (panel G),
primary tumor × 40 (panel H).
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